Sobi publishes Report for the First Quarter 2013

        Print
| Source: Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the
first quarter 2013. Revenues for the quarter totalled MSEK 528.5 (506.7), with
continued momentum across the commercial portfolio and several significant
advances in the pipeline.

Business Highlights
  * Received FDA approval of Kineret® for the treatment of NOMID.
  * Presented new phase 3 Haemophilia data, reinforcing long-lasting protection
    from bleeding for patients.
  * Received EMA approval to manufacture Kineret drug substance with partner
    Boehringer Ingelheim.
  * Entered into three key partnerships which further strengthen the partner
    network across the portfolio.


Financial Highlights
  * Total revenues increased by 4 percent to MSEK 528.5 (506.7). Adjusted for
    one-time items in the prior year, revenues increased 12 percent.
  * Gross margin increased to 57 percent (51) driven by efficiency gains in
    production and completion of technology transfer for Kineret.
  * Ended the quarter with a cash position of MSEK 401.2.
  * Outlook for 2013 remains unchanged.


"The quarter demonstrated continued commercial momentum, with 4 percent growth
year over year and expansion of our Key Therapeutic Areas of Inflammation and
Genetics in existing and new markets," said Geoffrey McDonough, CEO and
President. "In addition, our pipeline posted several significant events
including the FDA approval of Kineret for the treatment of NOMID and the release
of additional data from the phase 3 trials of our long-lasting recombinant
clotting factors for Haemophilia."



---

Sobi's report for the first quarter 2013 can be found on
http://www.sobi.com/Investors--Media/Reports/

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with three late-stage biological
development projects within Haemophilia and Neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com

For more information please contact
 Media relations                      Investor relations

 Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
                                      Investor Relations

 T: +46 70 410 71 80                  T: +46 8 697 20 00

 oskar.bosson@sobi.com                jorgen.winroth@sobi.com



The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on 26 April 2013 at 8:00 CET


[HUG#1696590]